Monitor Standard BioTools' upcoming filings for the financial impact of the divestiture and the progress of the Treeline merger and Mass Cytometry sale, which are more material to the company's future.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $0.6108entry
- T+1 · 13d ago +0.85%α −0.80% · $0.6160
- T+5 · 7d ago +8.87%α +9.46% · $0.6650
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
ARCHIMED has completed its acquisition of Standard BioTools' Microfluidics Business, which will operate as a standalone entity named Biomark Scientific. The deal removes a business line from Standard BioTools, which retains its remaining operations and is simultaneously pursuing a merger with Treeline Biosciences and a sale of its Mass Cytometry business.
Key Facts
- ARCHIMED completed acquisition of Standard BioTools' Microfluidics Business.
- The business will operate independently as Biomark Scientific.
- Standard BioTools retains its remaining operations and is pursuing a merger with Treeline Biosciences and a sale of its Mass Cytometry business.
- No financial terms of the acquisition were disclosed.
Financial Impact
No financial terms disclosed; the divestiture removes a business line but its contribution to Standard BioTools' revenue is not stated.
Risk Factors
- No financial terms disclosed, making it impossible to assess the deal's materiality.
- The press release includes forward-looking statements about the Treeline merger and Mass Cytometry sale, which are subject to regulatory and stockholder approvals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394105 |
Track record
23 reports on LAB
7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today 425 Neutral 4/10 Entry price pending
- Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
- Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Viewing Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
- Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
- Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
- Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers